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Preface 
Cancer is the leading cause of death in economically developed countries 
and the second leading cause of death in developing countries. 12.6% of all 
deaths are caused by cancer, which is more than the percentage of deaths 
caused by HIV/AIDS, tuberculosis, and malaria put together. Although earlier 
detection and more options in treatment have been developed in recent years, 
the incident rate of cancer continues to increase largely due to the aging and 
growth of the world population and an increasing adoption of cancer-causing 
behaviors, particularly smoking, in developing countries. If the trend continues, 
15 million people will discover they have cancer in 2020. For the sake of 
human health, cancer is an urgent global issue needs to be solved. 
My scientific interest on cancer research has emerged since the first time I 
got involved in research when I was an undergraduate student in China, 
wherein I studied the effect of 5-azacytidine on the inhibition of DNA 
methylation in mice. After I came to Japan, I was lucky to get the chance to join 
the Human Biology PhD Program which encourages students to understand 
and solve the global issues including cancer. Although cancer research is a 
huge field which many researchers worldwide are working on, I will be happy 
to be one part of it.  
In this dissertation, I focused on the oncogenic functions of a potential 
oncogenic protein, Nucleophosmin (NPM1). NPM1 is a multi-functional protein 
that has been involved in various biological processes. my laboratory has 
contributed to identification of its functions in chromatin remodeling and 
ribosome biogenesis. Much of the interest in NPM1 has been bolstered by the 
fact that it is directly implicated in tumorigenesis. However, the mechanism 
underlying the oncogenic functions of NPM1 remain still poorly understood in 
spite of the observations that NPM1 overexpression in tumor cells increases 
cell growth and proliferation, and inhibits cell differentiation and apoptosis. This 
dissertation describes two projects aimed to contribute to understanding the 
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mechanism underlying the oncogenic functions of NPM1 in different 
perspectives. The first project (Chapter 1) entitled “Efficient DNA binding of 
NF-κB requires the chaperone-like function of NPM1”, revealed the function of 
NPM1 in NF-κB pathway, an oncogenic pathway plays important roles in both 
cancer development and inflammation. The second project (Chapter 2) entitled 
“Functional characterization and efficient detection of Nucleophosmin/NPM1 
oligomers”, revealed the function of NPM1 oligomerization for its histone 
chaperone activity and the dynamic change of NPM1 oligomerization under 
different cell stimuli. The oligomerization of NPM1 has been suggested to be 
important for its function in cancer, and that inhibition of NPM1 oligomerization 
could be the potential approach for cancer therapy. 
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Chapter 1: Efficient DNA binding of NF-κB requires the 
chaperone-like function of NPM1 
 
 
 
 
1-1. Abstract 
Although NPM1/nucleophosmin is frequently overexpressed in various 
tumors, the oncogenic role of NPM1 remains unclear. Here I report a new 
oncogenic role of NPM1 by revealing the link between NPM1 and nuclear 
factor-κB (NF-κB), a master regulator of inflammation. I found that NPM1 
knockdown decreased NF-κB-mediated transcription of selected target genes 
whose functions enriched in inflammation and immunity by decreasing the 
recruitment of NF-κB p65 to the gene promoters. NPM1 is directly associated 
with the DNA binding domain of p65 to enhance its DNA binding activity 
without being a part of the DNA-NF-κB complex, suggesting the 
chaperone-like function of NPM1 for NF-kB-mediated transcription. 
Furthermore, I demonstrated that NPM1 was required for efficient 
inflammatory gene expression induced by tumor necrosis factor alpha (TNF-α) 
and lipopolysaccharide in fibroblasts and macrophages. The NF-κB-mediated 
invasion of breast cancer cells was significantly decreased by NPM1 
knockdown. My study suggests a novel mechanistic insight into the 
NF-κB-mediated transcription and an oncogenic role of NPM1 in both tumor 
cells and the tumor microenvironment through the regulation of NF-κB. 
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1-2. Introduction 
   NPM1 is a highly abundant phosphoprotein that mainly resides in the 
nucleolus, but continuously moves between the nucleolus, the nucleoplasm, 
and the cytoplasm (1). My laboratory has identified NPM1 as a factor 
stimulating adenovirus chromatin remodeling and studied its functions in 
uninfected cells (2). It is a multifunctional protein involved in various cellular 
processes such as ribosome biogenesis (3,4), sperm chromatin remodeling (5), 
centrosome duplication (6), and DNA repair (7). Biochemically, NPM1 shows 
the histone chaperone activity (8), which is required for the regulation of 
chromatin structure. Histone chaperones bind directly to histones for their 
transfer to DNA to assemble chromatin without being incorporated into the 
chromatin. Most of the interest in NPM1 has been focused on its oncogenic 
functions. On the one hand, the genetic alterations of the NPM1 gene have 
been detected in various hematological malignancies, and strikingly, NPM1 is 
one of the most frequently mutated genes in acute myeloid leukemia (9). On 
the other hand, NPM1 is over-expressed in various solid tumors and has been 
proposed as a tumor marker (10). The expression levels of NPM1 have been 
reported to be regulated by the oncogene MYC (11) and to correlate with tumor 
recurrence and progression (12). However, the oncogenic functions of NPM1 
remain still poorly understood in spite of the observations that NPM1 
overexpression in tumor cells increases cell growth and proliferation, and 
inhibits cell differentiation and apoptosis (10). 
A transcription factor, nuclear factor-κB (NF-κB), plays a key role in tumor 
initiation (13), promotion, progression, and metastasis (14-16). In addition to its 
oncogenic functions in cancer cells, NF-κB contributes to tumorigenesis 
through the activation of inflammatory cells in the tumor microenvironment 
because of its central role in the immune system. Therefore, NF-κB has been 
suggested to be a key link between inflammation and cancer. NF-κB was 
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originally discovered as a site-specific DNA-binding protein complex that binds 
to the enhancer element of the immunoglobulin (Ig) kappa light-chain of 
activated B cells (17). The mammalian NF-κB family contains the following five 
proteins: 1) p65 (RelA); 2) c-Rel; 3) RelB; 4) p50; and 5) p52, which function as 
homo- or hetero-dimers to control gene transcription (18). The most abundant 
form of the NF-κB complex contains the p65–p50 heterodimer that regulates 
the genes including those for cytokines, chemokines, adhesion molecules, and 
enzymes that produce secondary inflammatory mediators. 
Achieving precise and sufficient gene regulation by NF-κB requires specific 
posttranslational modifications and interactions with cofactors (19). Indeed, it 
was predicted that the original size of the native NF-κB complex from nuclear 
extracts is much larger than that of the NF-κB p65–p50 heterodimer. Moreover, 
the native NF-κB complexes have a higher affinity for the Ig κB DNA motif than 
the reconstituted p65–p50 heterodimer does (20,21), which highlights the 
importance of cofactors for NF-κB DNA binding. It has been reported that 
ribosomal protein S3 (22), Sam68 (23), telomerase (24), and cyclin dependent 
kinase 6 (25) directly associate with the NF-κB complex and enhance its DNA 
binding activity.  
It was also observed that a nucleolar protein nucleophosmin/B23/NPM1 
interacts with NF-κB and regulates the expression of the SOD2 gene (26), 
however, whether NPM1 regulates the NF-κB pathway and the effect of NPM1 
on NF-κB-mediated transcriptome are still unknown. In this study, I aimed to 
reveal the role of NPM1 in the NF-κB pathway and its effect on 
NF-kB-mediated transcriptome. My findings are important for two main 
reasons: 1) NF-κB, a master regulator of inflammation, requires the 
chaperone-like activity of an oncogenic protein NPM1 for its functions and; 2) 
two oncogenic factors, NPM1 and NF-κB, are suggested to cooperatively 
regulate tumor progression through cancer cells and the tumor 
microenvironment. 
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1-3. Materials and Methods 
1-3-1. Plasmid constructs 
Plasmids pET-14b-B23.1, pGEX2T-B23.1, pGEX2T-B23.2, pGEX2T-B23.3, 
pGEX2T-B23.1-CR and pGEX2T-B23.1-ΔA1A2 have been described 
previously (27). To construct pGEX2T-B23.1-ΔN, B23.1-ΔN fragment was cut 
out from template plasmid pET14b-B23.1-ΔN (27) by BamH I and cloned into 
the same site of pGEX2T vector. The p65/RelA, RelB, c-Rel, and p50 genes 
were cloned by PCR using primer sets 
5’-ATGCGGATCCATGGACGAACTGTTCCCCCT-3’ and 5’- 
ATGCGGGATCCTTAGGAGCTGATCTGACTCA-3’, 
5’-AAAGAATTCATGCTTCGGTCTGGGCCAGC-3’ and 
5’-AAAGAATTCCTACGTGGCTTCAGGCCCCG-3’, 
5’-AAAGGATTCATGGCCTCCGGTGCGTATAA -3’ and 
5’-AAAGAATTCTTATACTTGAAAAAATTCAT -3’, and 
5’-AAAGAATTCATGGCAGAAGATGATCCATA-3’ and 
5’-AAACTCGAGTAGGTTCCATGCTTCATCCCAG-3’, respectively. The 
amplified p65, RelB, c-Rel, and p50 cDNA fragments were subcloned into the 
BamH I-digested, EcoR I-digested, BamH I and Eco RI-digested, and EcoR I 
and Xho I digested pcDNA3.1-Flag vector. The p65 and p50 cDNAs were also 
cloned into pcDNA3-HA vector. To construct vectors expressing p65 deletion 
mutants, deletion mutant fragments were cloned by PCR using primers 
5’-ATGCGGATCCATGGACGAACTGTTCCCCCT-3’ and 
5’-AAAGGATCCTTAAGAAAGGACAGGCGGCAGGC-3’ for p65-N1 
(a.a.1–180), 5’-AAAGGATCCCATCCCATCTTTGACAATCG-3’ and 
5’-AAAGGATCCTTAAGAAGCTGAGCTGCGGGAAG-3’ for p65-N2 
(a.a.181–340), 5’-AAAGGATCCGTCCCCAAGCCAGCACCCCA-3’ and 
5’-ATGCGGGATCCTTAGGAGCTGATCTGACTCA-3’ for p65-C (a.a. 341-551), 
p65 forward primer and p65-N2 reverse primer for p65-N (a.a.1–340), p65-N2 
forward and p65 reverse primers for p65-N2C (a.a.181–551), the amplified 
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cDNAs were subcloned into the BamH I sites of pcDNA3.1-Flag and pET14b 
vectors. All the plasmids were confirmed by DNA sequencing. 
 
1-3-2. Animals, cell culture, transfection, and reagents 
C57BL/6J-ApcMin/+ mice were purchased from the Jackson Laboratory. The Min 
pedigree was maintained by mating C57BL/6J wild type females with 
C57BL/6J-ApcMin/+ males, genotype analysis was performed using a PCR 
assay as described (28). Colon adenomas were developed by administration 
of 2% Dextran Sulfate Salt in drinking water for 7 days during 5th week of age. 
Mice were sacrificed at 8 weeks of age and subjected to histological analyses. 
BDF-1 mice were purchased from CLEA Japan, Inc. HeLa, HEK293T, BT-20, 
MDA-MB-157, MDA-MB-231, MDA-MB-436 cells, and p53-/- and p53-/-NPM1-/- 
mouse embryonic fibroblast (MEF) cells were cultured in DMEM supplemented 
with 10% heat-inactivated fetal bovine serum (FBS) at 37ºC with 5% CO2. 
Primary macrophages were prepared from wild type BDF-1 mice (10-week old) 
injected with 3.84% (w/v) thioglycollate 3 d after injection. PBS (5 ml) was 
injected into peritoneal cavity and recovered. Cells were centrifuged and 
seeded in RPMI1640 medium (GIBCO) supplemented with 10% FBS, and 
incubated at 37ºC for 0.5 h. Non-adherent cells were removed by wash with 
PBS, and cells were maintained in the same medium. 
 
1-3-3. Transfection and reagents 
Transfection of plasmid DNA and siRNAs were performed by GeneJuice 
(Novagen) and Lipofectamine RNAiMAX (Life technologies), respectively, 
according to the manufacturer’s instructions. Stealth RNAs for negative 
controls and human NPM1 were described previously (29). Mouse NPM1 
(siRNA ID: s124573) and human NF-κB p65 (HSS109159) were obtained from 
Life technologies. Antibodies used were NPM1 (Invitrogen), Flag tag (M2, 
Sigma Aldrich), p65 (ab7970, Abcam), I-κBα (sc-371, Santa Cruz), and β-actin 
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(sc-47778, Santa Cruz). Recombinant human TNF-α(PEPROTECH) and 
Lipopolysaccharide (LPS) (Sigma) were commercially available. 
 
1-3-4. Preparation of proteins 
Purifications of GST-tagged proteins and his-tagged proteins were described 
previously (30). For purification of Flag-tagged proteins, HEK 293T cells 
transfected with appropriate expression vectors were suspended in buffer A 
(0.1% Triton X-100, 20 mM Tris-HCl pH7.9, 10 mM KCl, 1.5 mM MgCl2, 0.5 
mM PMSF) containing 400 mM NaCl on ice for 10 min and rotate at 4ºC for 30 
min followed by centrifuge at 15k rpm, 4ºC for 15 min. The supernatants were 
recovered and diluted with twice volumes of buffer A without NaCl. The cell 
extracts were incubated with anti-Flag M2 affinity gels (SIGMA–ALDRICH) for 
2 h at 4ºC and then washed by buffer B (0.1% Triton X-100, 50 mM Tris-HCl 
pH7.9, 0.5 mM PMSF) containing 300 mM NaCl. The proteins bound with the 
resin were eluted with buffer A containing 150 mM NaCl and Flag peptide 
(SIGMA–ALDRICH), dialyzed against buffer H (20 mM Hepes–NaOH pH 7.9, 
50 mM NaCl, 0.5 mM EDTA, 1 mM DTT, 0.1 mM PMSF and 10% Glycerol). 
 
1-3-5. Immunoprecipitation and GST-pull down assay 
HEK293T cells transfected with the expression vectors for Flag-p65, Flag-p50, 
HA-p65 or Flag-p65 deletion mutants were sonicated in buffer B containing 
150 mM NaCl. The cell lysates were incubated with anti-Flag M2 affinity gels 
(SIGMA–ALDRICH) in buffer A for 1 h at 4ºC, and the resins were then washed 
with the same buffer. The proteins bound with the resin were eluted with buffer 
B containing Flag peptide (SIGMA–ALDRICH), separated by SDS-PAGE and 
detected by western blotting. For GST-pull down assays, GST, GST-NPM1 or 
GST-NPM1 deletion mutants was incubated with glutathione-sepharose beads 
in buffer A for 45 min and washed with buffer A twice. The beads were mixed 
with Flag-p65, RelB, or c-Rel and incubated at 4ºC for 2 h followed by 
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extensive washing with the same buffer. Proteins were eluted from the beads 
by a SDS sample buffer, separated by SDS-PAGE, and visualized by CBB 
staining and western blotting. 
 
1-3-6. Reporter assay 
HeLa cells (3x104 per well) were seeded in 24-well plates and transfected with 
80 ng of pNF-κB-TA-Luc (Firefly luciferase) and 20 ng of pTA-RL (Renilla 
luciferase) at 48 h after transfection with siRNA for NPM1 or negative control. 
Sixteen hours after transfection, cells were treated with 20 ng/ml TNF-α for 
different time courses as described in the legend. Luciferase assay was 
performed using Renilla Luciferase Assay System kit (Promega Corporation, 
USA) according to the manufacturer’s instructions. The sane experiments 
were performed with p53-/- and p53-/-NPM1-/- MEFs. 
 
1-3-7. RT-qPCR 
Total RNA was extracted using RNeasy Kit (Qiagen) according to the 
manufacturer’s instructions. cDNA was prepared from purified RNA (1 g) by 
using ReverTraAce (Toyobo) with oligo dT primer. Real-time PCR was carried 
out in triplicate with primers (sequences are shown in Table S1) by using 
SYBR Green Realtime PCR Master Mix-Plus (Toyobo) in the Thermal Cycler 
Dice Real-Time PCR system (TaKaRa).  
 
1-3-8. Chromatin Immunoprecipitation (ChIP) 
ChIP was performed with HeLa cells treated with or without TNF-αCells were 
fixed with 1.4% formaldehyde at room temperature for 10 min, the whole cell 
lysates were sonicated to generate DNA fragments 200–1000 base pairs in 
length. The sonicated lysates were used for ChIP with anti-p65, anti-NPM1 or 
IgG control antibodies. After washing, the complexes were eluted, protein-DNA 
crosslink was reversed, and DNA was purified and used for quantitative PCR. 
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Primer sequences used for PCR were shown in Table S2. 
 
1-3-9. EMSA 
Radio-labeled double-stranded oligonucleotide probes wt Ig κB 
(5’-AGTTGAGGGGACTTTTCCCAGG-3’) and mutant Ig κB 
(5’-AGTTGAATCCACTTTCCCAGG-3’) were used for EMSA. EMSA was 
carried out as previously described (22). Briefly, p65 or p50 protein (20 
ng/sample) was incubated with the purified GST, GST-NPM1, or His-NPM1 
protein at 25ºC for 30 min, followed by additional incubation with [32P]-labeled 
Ig κB (WT) or Ig κB (Mut) oligonucleotide at 25ºC for 30 min. Samples were 
resolved on a 6% native PAGE in 0.5xTBE buffer.  For supershift analyses, 
recombinant proteins were preincubated with 0.2 g of antibodies for 20 min 
on ice prior to the addition of labeled probes. 
 
1-3-10. Immunofluorescence and Proximity Ligation Assays 
Cells on cover slips were fixed with 3% paraformardehyde in PBS, and 
permeabilized in PBS containing 0.5% Triton X-100. The cells on coverslips 
were then incubated with anti-NPM1 and p65 antibodies diluted with PBS 
containing 0.5% non-fat dry milk. Localization of proteins was visualized with 
secondary antibodies conjugating with AlexaFluor dyes (Molecular Probes). 
During final wash with PBS containing 0.1% Triton X-100, DAPI DNA staining 
dye was added and incubated for 15 min at room temperature. In situ proximity 
ligation assay (PLA) kit (Sigma-ALDRICH) was used to detect protein-protein 
interaction in fixed cells according to the manufacturer’s instructions. PLA 
signals were quantitatively analyzed by the image processing software Imaris 
(Carl Zeiss microimagining). Localization of proteins, DNA, and PLA signals 
was observed under confocal microscope (LSM EXCITER; Carl Zeiss 
Microimaging, Inc.). 
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1-3-11. Microarray hybridization and data analysis 
HeLa cells were incubated with NPM1 or control siRNA for 72 h and treated 
without or with 20 ng/ml TNF-α for 2 h. Total RNA was then isolated using 
RNeasy Kit (Qiagen) according to the manufacturer’s instructions. The 
sense-strand cDNA was prepared using Ambion WT Expression Kit from 200 
ng total RNA. The cDNA was then fragmented and labeled using the Affymetrix 
GeneChip WT Terminal Labeling Kit. The fragmented and labeled cDNA was 
injected to the Gene Arrays 1.0 ST and incubated at 45ºC with 60 rpm for 17 hr. 
The hybridized samples were washed and stained using Affymetrix fluidics 
station 450. GeneChips were scanned using Affymetrix GeneArray Scanner 
3000 7G Plus. All kits were obtained from Affymetrix (Santa Clara, CA) and 
experiments were performed according to the manuals. Raw data were 
analyzed using the rma() function in R-Bioconductor (31) package “affy” (32,33) 
with default setting. Background correcting was processed by the RMA (robust 
multichip averaging) (34), the data were normalized by quantiles, and the 
signal intensity of each probe set was obtained by the method medianpolish. 
The annotation of probe sets was performed by Bioconductor 
hugene10sttranscriptcluster.db. The microarray data are available at the NCBI 
Gene Expression Omnibus (GEO) under accession number GSE81785. Gene 
ontology analysis was performed using DAVID (The Database for Annotation, 
Visualization and Integrated Discovery) (http://david.abcc.ncifcrf.gov/) (35,36). 
 
1-3-12. Immunohistochemistry (IHC) 
Apcmin/+ mice (12-weeks old) were given 2% (w/v) DSS in drinking water for 1 
week, then changed to normal drinking water for 2 weeks. Colon tissues from 
the mice were cut and opened, fixed in phosphate-buffered 10% formalin and 
embedded in paraffin and cut into 5-m sections. The sections were dewaxed, 
rehydrated, and immersed in 3% hydrogen peroxide for 20 minutes to quench 
endogenous peroxidase activity. Antigen retrieval was performed at 95ºC for 
20 minutes in sodium citrate buffer (pH 6.0). The sections were incubated with 
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blocking buffer (PBS supplemented with 2% goat serum and 1% bovine serum 
albumin) for 1 hour, anti-NPM1 or p65 antibodies for 1 hour at RT, a 
biotinylated secondary antibody for 45 min, and peroxidase-conjugated 
streptavidin solution for 45 min. Protein localization was visualized with 3, 
3-diaminobenzidine and sections were lightly counterstained using Gill’s 
haematoxylin. 
 
1-3-13. Matri-gel invasion assay 
Invasion assays were performed using transwell chambers (24-well insert; 
pore size, 8 μm; Corning-Costar, Corning, NY, USA). Transwell membrane was 
coated with 30 g of matrigel and incubated at 37ºC for 3 h. MDA-MB-231 cells 
(5x104) in 200 l of serum-free medium were seeded into the upper chamber 
of the transwell and medium supplemented with serum was used as a 
chemoattractant in the lower chamber. The cells on the upper chamber were 
treated with or without TNF-, incubated for 16 h, and cells that did not invade 
through the pores were removed with a cotton swab. Cells on the lower 
surface of the membrane were fixed with methanol and stained with 0.05% 
crystal violet. The stained cells were counted under a microscope (Leica Dmi8) 
in 3 random fields/well. 
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1-4. Results 
1-4-1. Interaction between NPM1 and NF-κB 
A previous study showed that NPM1 interacts with the NF-κB subunits p65 
and p50 (26). However, whether NPM1 also interacts with other NF-κB family 
proteins and the interaction is direct or not have never been examined. I first 
examined the interaction between NPM1 and the NF-κB family Rel proteins, 
p65 (RelA), RelB, and c-Rel. Flag-tagged p65, RelB, and c-Rel were purified 
(Fig. 1A) and a glutathione S-transferase (GST) pull down assay was 
performed. All Flag-tagged p65, RelB, and c-Rel were more efficiently 
precipitated with GST-NPM1 than GST. Flag-p65 precipitated by GST-NPM1 
was much more efficient than Flag-RelB and Flag-c-Rel (Fig. 1B), suggesting 
that NPM1 preferentially associates with p65. I next confirmed the interaction 
between NPM1 and the classic NF-κB complex proteins p65 and p50 by 
co-immunoprecipitation with the exogenous Flag-tagged NF-κB proteins. 
NPM1 was co-immunoprecipitated with both Flag-p65 and Flag-p50 (Fig. 1C, 
lanes 6–7). When Flag-p50 and HA-p65 were co-expressed and 
immunoprecipitated with anti-Flag antibody, HA-p65 and NPM1 were 
immunoprecipitated with Flag-p50 (lane 8). I also found that NPM1 directly 
interacted with p65 and p50 with similar efficiency (Fig. 1D). Furthermore, in 
situ proximity ligation assay (PLA) using antibodies for both NPM1 and p65 
revealed that NPM1 interacted with p65 mainly in the nucleus (Fig. 1E, top 
panels). Treatment of cells with TNF-α, which activates the NF-κB pathway, 
dramatically enhanced the interaction (Fig. 1E, bottom panel and Fig. 1F). The 
PLA signals were mainly detected in the nucleoplasm, indicating that this is 
where the interaction between p65 and NPM1 occurred. Because NPM1 is 
mainly localized in the nucleolus, we tested whether NPM1 localization was 
changed upon treatment of cells with TNF-α. HeLa cells stably expressing 
enhanced green fluorescent protein (EGFP)-NPM1 were treated with TNF-α 
and the localizations of p65 and EGFP-NPM1 were examined (Fig. 1G). p65 
was translocated to the nuclei 15 min after TNF-α treatment. I found that 
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although the interaction between p65 and NPM1 occurred in the nucleoplasm 
(Figs. 1E and F), TNF-α treatment did not clearly change the localization of 
EGFP-NPM1. 
 
1-4-2. NPM1 regulates NF-κB-dependent gene transcription 
I next examined the effect of RNAi-mediated knockdown of NPM1 on the 
expression of NF-κB-dependent reporter gene expression in HeLa cells. NPM1 
siRNA significantly decreased the total amount of NPM1 compared with the 
nonspecific (NS) control siRNA (Fig. 2A). The reporter activity was found to be 
decreased by NPM1 knockdown even in the absence of TNF-α. As expected, 
TNF-α treatment induced the NF-κB-driven luciferase activity in NS 
siRNA-treated cells, but this induction was significantly decreased in NPM1 
siRNA-treated cells (Fig. 2B). 
I performed microarray analysis to comprehensively analyze the effect of 
NPM1 knockdown on the NF-κB-dependent gene expression induced by 
TNF-α treatment in HeLa cells. I found that without TNF-α treatment, 288 
genes were up-regulated (>1.5-fold) and 359 genes were down-regulated 
(<0.667-fold) by NPM1 knockdown (Fig. 2D), suggesting that NPM1 is involved 
in the regulation of a variety of genes. Upon stimulation with TNF-α, 77 genes 
were up-regulated (>1.5-fold) and 13 genes were down -regulated (<0.667-fold) 
(Fig. 2C). In addition, in TNF-α treated cells, NPM1 knockdown decreased the 
expression of 445 genes (<0.667-fold) and increased the expression of 223 
genes (>1.5-fold) (Fig. 2E). Among the 77 genes up-regulated by TNF-α 
treatment, 32 genes were down-regulated (>1.5-fold) by NPM1 knockdown 
(Fig. 2F, upper panel) and only two genes were up-regulated (>1.5-fold) by 
NPM1 knockdown. When the cutoff fold-change (chip2 vs chip4) was set to 1.2, 
the number of the genes down- regulated by NPM1 knockdown was increased 
to 55, while only seven genes were up-regulated (>1.2-fold) by NPM1 
knockdown (Fig. 2I). These results suggested that NPM1 is involved in the 
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regulation of most, but not all, genes stimulated by TNF-α treatment. The heat 
map shows the expression of the 32 genes sorted by the fold change values 
(Figs. 2G and 2H) between control and NPM1 knockdown in TNF-α-treated 
cells. Many of them are cytokines, such as IL-8, TNF-α, and IL-6. Indeed, gene 
ontology (GO) analysis of the 32 TNF-α-induced genes whose expressions 
were down-regulated (>1.5-fold) by knockdown of NPM1 showed functional 
enrichment in inflammation and immunity such as cytokine activity, cytokine, 
inflammatory response, response to wounding, and defense response (Fig. 2F, 
lower panel). To confirm the microarray analyses, reverse 
transcriptase-mediated polymerase chain reaction (RT-PCR) was performed 
(Fig. 2J). The expressions of eight genes (IGFL1, SELE, CCL2, RND1, PLAU, 
IL-8, TNF-α, and CCL20) were confirmed to be significantly reduced by NPM1 
knockdown. In addition, I confirmed that the expression levels of NR4A2 and 
DUSP5 were slightly increased by NPM1 knockdown. It should be noted that 
the increase or decrease of those genes was observed even in the absence of 
TNF-α treatment. 
To explore the mechanism by which NPM1 regulates the expression of the 
genes stimulated by TNF-α, I examined whether NPM1 knockdown affected 
the NF-κB signaling pathway such as I-κB protein degradation, NF-κB nuclear 
translocation, and NF-κB recruitment to its target genes upon stimulation by 
TNF-α. The I-κB proteins bind NF-κB to retain it in the cytoplasm and are 
quickly degraded upon stimulation by TNF-α through the ubiquitin-proteasome 
system to allow the nuclear translocation of NF-κB. The I-κB genes are target 
genes of the NF-κB complex and the I-κB–NF-κB complex constitutes a 
feedback oscillatory circuit (37). Indeed, I-κBα was quickly degraded upon 
TNF-α treatment and the expression was recovered within 60 min, and the 
oscillatory expression was observed with peak expressions at 60 min and 105 
min (Fig. 3A). I found that I-κBα protein degradation was similarly observed 15 
min after TNF-α stimulation regardless of the level of NPM1 expression (Fig. 
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3A, lane 2). However, the pattern of oscillatory expression of I-κBα was 
changed by NPM1 knockdown, suggesting that NPM1 is involved in the I-κBα 
expression. Likewise, the nuclear translocation of NF-κB p65 upon TNF-α 
treatment was not affected by knockdown of NPM1 (Fig. 3B). I then examined 
whether NPM1 affected the binding of NF-κB to target gene promoters by 
chromatin immunoprecipitation (ChIP). In unstimulated cells, a low but distinct 
amount of p65 was detected at the promoter regions of TNF-α, PLAU, IL-8, 
NR4A2, and DUSP5 genes. Upon stimulation with TNF-α, the binding of p65 to 
these genes was significantly increased. However, NPM1 knockdown 
decreased the p65 binding to the TNF-α, PLAU, and IL-8 gene promoters in 
both unstimulated and TNF-α-stimulated cells. In contrast, the recruitment of 
p65 to the promoter regions of NR4A2 and DUSP5 was not affected by 
knockdown of NPM1 (Fig. 3C). These results indicate that NPM1 stimulates 
the binding of NF-κB to a subset of NF-κB target gene promoters. I noted that 
the expression of NR4A2 and DUSP5 was increased by NPM1 knockdown 
regardless of TNF-α treatment (Fig. 2J), whereas the promoter binding of p65 
to these genes was not significantly affected. These results indicate that NPM1 
suppresses these genes independent of the promoter binding of NF-κB. 
 
1-4-3. NPM1 enhances the DNA binding activity of NF-κB 
Considering the effect of NPM1 on the binding of NF-κB to target gene 
promoters in vivo and its direct interaction with NF-κB in vitro, I next examined 
whether NPM1 affected the binding of NF-κB to the κB site in vitro by the 
electrophoretic mobility shift assay (EMSA) using purified recombinant NF-κB 
proteins and His-NPM1 (Fig. 4A). When either Flag-p65 or Flag-p50 was 
expressed, a homo-dimer of Flag-tagged proteins and a minor population of a 
heterodimer of Flag-tagged proteins and endogenous p65 or p50 were purified 
(Fig. 4A, lanes 2 and 3). When Flag-p50 and HA-p65 were co-expressed and 
purified with anti-Flag affinity gel, the Flag-p50 homodimer and the 
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heterodimer of Flag-p50 and HA-p65 were purified (Fig. 4A, lane 4). All purified 
p50 homodimer, p65 homodimer, and p65-p50 heterodimers specifically bound 
to the κB oligonucleotide (Fig. 4B, lanes 2 and 5), but not to the mutant κB 
oligonucleotide (lanes 3 and 6). The addition of anti-p65, anti-Flag tag, or 
anti-HA tag antibody induced supershift, thereby ensuring the binding of 
specific NF-κB dimers to the κB oligonucleotide (lanes 4 and 7–9). NPM1 
significantly increased the binding of all NF-κB dimers to the κB oligonucelotide 
in a dose dependent manner (Fig. 4C), whereas NPM1 itself did not bind to the 
κB oligonucleotide (Fig. 4C, lane 1). 
To test whether NPM1 is included in the NF-κB/DNA complex, EMSA with 
or without anti-NPM1 was performed (Fig. 4D). The Flag-p65 homodimer and 
Flag-p50–HA-p65 heterodimers were bound to the κB oligonucleotide, which 
was enhanced by NPM1 (Fig. 4D, lanes 2, 3, 6, and 7). The addition of Flag 
antibody, but not NPM1 antibody, induced a supershift of the complex 
containing DNA and the NF-κB proteins (Fig. 4D, lanes 4, 5, 8 and 9). 
Considered together, these results indicated that NPM1 binds directly to and 
enhances the DNA binding activity of the NF-κB proteins without being 
incorporated into the NF-κB/DNA complex. 
To further explore whether NPM1 is incorporated into the NF-κB/DNA 
complex in vivo, I next performed ChIP assays with antibodies against 
endogenous p65 and NPM1 (Fig. 4E). The binding of p65 to the PLAU and IL-8 
gene promoters, but not to the ribosome RNA gene (rDNA), was increased 
upon TNF-α treatment in a time-dependent manner. NPM1 showed constant 
binding to rDNA as previously reported (3), but was not recruited to the PLAU 
and IL-8 gene promoters during the entire time course after TNF-α treatment. 
These results support my conclusion that NPM1 is not included in the 
NF-κB/DNA complex. 
 
21 
 
1-4-4. NPM1 and κB DNA compete for binding to NF-κB 
   I next attempted to clarify the mechanism by which NPM1 enhances the DNA 
binding activity of NF-κB. To this end, we first determined the NF-κB binding domain of 
NPM1 by a GST-pull down assay with the NPM1 deletion mutant proteins (Fig. 5A). A 
splicing variant of NPM1/B23.1 termed B23.2 that lacks the C-terminal RNA binding 
domain interacted with p65, indicating that the C-terminal RNA binding domain is 
dispensable for p65 binding (Fig. 5B, lane 7). Further analyses suggested that the 
N-terminal oligomerization domain and acidic regions were also dispensable for p65 
binding and the C-terminal region termed NPM1-CR was sufficient to interact with p65 
in vitro (Fig. 5B, lanes 2–6). 
Next, the NPM1 binding domain of p65 was determined by immunoprecipitation 
assay. Flag-tagged p65 proteins were expressed in 293T cells and 
immunoprecipitated with anti-Flag antibody followed by western blotting with 
anti-NPM1 antibody (Figs. 5C and D). Consistent with the data shown in Fig. 1C, 
NPM1 was co-precipitated with full length p65. The N-terminal domain of p65 (p65-N1) 
that contains the DNA binding domain of p65, but not the dimer formation domain 
without or with the activation domain (p65-N2 or p65-N2C, respectively), 
co-precipitated with endogenous NPM1. The N-terminal domain with the dimer 
formation domain (p65-N) also efficiently co-precipitated NPM1, indicating that NPM1 
interacts with the DNA binding domain of p65. 
Because NPM1 interacts with the DNA binding domain, I next questioned whether 
the N-terminal domain is sufficient for NPM1 to enhance the DNA binding activity of 
p65. NPM1 increased the binding of p65-N to the κB DNA in a dose dependent 
manner (Figs. 6A and B), suggesting that the C-terminal activation domain of p65 is 
dispensable for NPM1 to enhance the DNA binding activity of p65. 
Given that NPM1 directly interacted with the DNA binding domain of p65 and that 
NPM1 was not incorporated into the NF-κB/DNA complex, it was speculated that 
NPM1 and DNA compete for the binding to NF-κB. This speculation was first 
examined by gel shift assay using purified p65-N and NPM1 (Fig. 6C). NPM1 is an 
acidic protein and migrated to the cathode in native gel, whereas p65-N entered the 
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gel inefficiently (lanes 1 and 2). The mobility of NPM1 was shifted upon addition of 
p65-N in a dose dependent manner (lanes 2–5). However, the addition of κB DNA 
increased free NPM1 and the DNA-p65-N complex appeared (lanes 6–8). Taken 
together, these results suggest that the chaperone-like function of NPM1 is required 
for the efficient DNA binding of NF-κB. To further confirm this conclusion, disruption of 
NPM1-p65-N complex by the κB DNA oligonucleotide was examined using purified 
proteins and oligonucleotide (Fig. S4). The p65-N protein bound to GST-NPM1 was 
eluted in the supernatant in an oligonucleotide concentration-dependent manner. 
Because the mutant κB DNA did not efficiently compete with NPM1 for the binding to 
p65-N, NPM1 transferred the p65-N protein preferentially to the κB DNA. 
To clarify the mechanism by which NPM1 regulates a subset of NF-κB target 
genes, EMSA assays were performed using the κB site DNA fragments derived from 
Ig, IL-8, and NR4A2 genes (Fig. 6D). The p65-N protein bound to all three κB site 
DNAs with similar efficiency. Interestingly, NPM1 significantly enhanced the binding of 
p65 to Ig and IL-8 κB sites, whereas the effect of NPM1 on the binding of p65-N to the 
NR4A2 κB site was very low (Fig. 6E). This result indicates that the κB sequence or 
the sequence around it determines the requirement of NPM1 for the efficient p65 
binding to its target sites. 
 
1-4-5. NPM1 abrogates the intramolecular interaction of p65 
   It was previously reported that the intramolecular interaction between the 
N- and C-terminal domains of p65 blocks the binding of CBP/p300 to the p65 
protein (38). This suggests that the formation of the transcription activation 
complex is controlled by the intramolecular interaction of p65. Considering that 
NPM1 interacts with the N-terminal domain of p65, I speculated that NPM1 
might compete with the C-terminal domain of p65 for the binding to the 
N-terminal domain of p65, thus blocks the intramolecular interaction of p65 to 
enhance the assembly of the transcription activation complexes. To examine 
this, gel shift assay was performed using purified NPM1, p65-N, and p65-C 
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(Fig. 7A). Free p65-C migrated to the cathode and the p65-C band was shifted 
upon addition of p65-N in its dose-dependent manner (lane 2–5), ensuring the 
interaction between p65-N and p65-C. Interestingly, the addition of NPM1 
increased free p65-C (lanes 6–8) and the NPM1-p65-N complex appeared, 
indicating that NPM1 abrogates the intramolecular interaction between p65-N 
and -C. From these results, it is suggested that the p65 subunit of NF-κB 
translocated to the nuclei upon various stimuli is bound by NPM1. NPM1 
enhances the DNA binding of NF-κB via its chaperone-like function and 
simultaneously abrogates the intramolecular interaction of p65 to enhance the 
assembly of the transcription activation complexes (Fig. 7B). 
 
1-4-6. Functional intersection between NPM1 and NF-κB 
Because NF-κB is a crucial regulator of tumor formation, progression, and 
migration (39), and NPM1 is highly expressed in cancer cells (10), I next 
investigated the biological significance of the interaction between NF-κB and 
NPM1 in cancer. I first examined the expression of NPM1 and NF-κB in normal 
colon and adenomas obtained from multiple intestinal neoplasia (min) mice 
carrying a mutation in the adenomatous polyposis coli gene (Apcmin/+ mice) 
treated with dextran sodium sulfate, an inducer of colitis (Fig. 8A). The normal 
colon epithelium (Fig. 8A, lower section of the pictures) showed uniform crypts, 
whereas the crypt structures were disorganized in the adenomas (upper 
section of the pictures). Hematoxylin and eosin (HE) staining clearly 
demonstrated that the cells in adenomas exhibited slightly larger nuclei, 
prominent nucleoli, and intensely colored cytoplasm. I found that much 
stronger expression of both the p65 subunit of NF-κB and NPM1 was detected 
in adenomas than in normal colon. Both proteins were also detected at high 
levels in stromal cells. Importantly, p65 was mainly detected in the nucleus in 
stromal cells in adenomas, suggesting that NF-κB was activated in stromal 
cells. Given that tumor cells are associated with a heterogeneous mixture of 
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stromal cells that include fibroblasts and immune cells, it was possible that 
NPM1 and NF-κB cooperatively induce cancer progression by the functions of 
stromal cells. To examine this possibility, I tested the functional interaction 
between NPM1 and NF-κB in both mouse embryonic fibroblasts (MEFs) and 
peritoneal macrophages. I used p53-/- and p53-/-NPM1-/- MEFs to examine the 
effect of NPM1 depletion on the NF-κB-driven luciferase expression. NPM1-/- 
MEFs undergo cell cycle arrest due to p53 activation and can grow only when 
p53 is also depleted (40). Consistent with the results in HeLa cells, both TNF-α 
and LPS stimuli induced the NF-κB-driven luciferase activity in p53-/- control 
MEFs (Fig. 8C). However, the reporter activities induced by both stimuli were 
significantly lower in p53-/-NPM1-/- MEFs than those in p53-/- control MEFs (Fig. 
8C). Next, mouse peritoneal macrophages were treated with control or NPM1 
siRNAs and the expression of NPM1 was examined by western blotting (Fig. 
8D). NPM1 expression was clearly decreased by NPM1 siRNA treatment, 
whereas that of actin was unchanged. The expressions of NF-κB target genes 
TNF-α, IL-1β, IL-6, and IFN-βbut not GAPDH, were significantly induced by 
LPS (Fig. 8E, lanes 1 and 2). The induced expressions of TNF-α, IL-1β, and 
IFN-β were significantly decreased by NPM1 knockdown, whereas the 
expression of the IL-6 gene was not significantly affected. Considered together, 
my results demonstrated that NPM1 and NF-κB cooperatively regulate the 
inflammatory responses both in fibroblasts and macrophages. 
I next examined the functions of the NPM1-NF-κB complex in cancer cells. 
The expression level of NPM1 in various breast cancer cell lines were 
examined using the GOBO database (41), because breast cancer cells having 
‘triple negative’ phenotype, namely no expression of estrogen receptor, 
progesterone receptor, and ERBB2, show constitutive activation of the NF-κB 
activity (42). Previous study showed that NPM1 is highly expressed in normal 
luminal epithelial cells and its expression is induced by hormones (43). 
However, among commonly used 51 breast cancer cell lines, the expression of 
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NPM1 was highest in the basal B subtype cell lines that show ‘triple negative’ 
phenotype and exhibit a stem cell-like gene expression profile (44), and was 
the lowest in luminal subtype cell lines that show more differentiated and non 
invasive phenotype (Figs. 9A and 9B) (44). To confirm the expression of NPM1 
in basal A- or B-type breast cancer cell lines (BT20, MDA-MB-157, 
MDA-MB-231, and MDA-MB-436), RT-PCR and western blotting were 
performed (Fig. 8F).  The results indicated that the expression of NPM1 was 
the highest in MDA-MB436 cells among the 4 cell lines tested. The previously 
determined constitutive NF-κB activity of these cells (42) were plotted against 
NPM1 mRNA level (Fig. 8G). The constitutive NF-κB activity was correlated 
with the expression level of NPM1, although the expression level of p65 was 
not very high in MDA-MB-436 cells (Figs. 8H and G).  These results support 
the idea that NPM1 is a positive regulator of the NF-κB complex. 
Because NF-κB has been reported to regulate cancer cell migration and 
invasion (39), I examined the effect of NPM1 knockdown on TNF-α-induced 
cancer cell invasion by matrigel invasion assays using a breast cancer cell line, 
MDA-MB-231 (Figs. 10B and 8H). I demonstrated that TNF-α treatment 
significantly enhanced the invasion of MDA-MB-231 cells. Upon knockdown of 
NF-κB p65, the TNF-α induced invasion of MDA-MB-231 cells was greatly 
reduced, indicating that the invasion enhanced by TNF-α was 
NF-κB-dependent. Knockdown of NPM1 or double knockdown of NPM1 and 
p65 both blocked the TNF-α induced invasion, suggesting that NPM1 
regulates cancer cell invasion through enhancing NF-κB signaling. The 
expression level of p65 and NPM1 by siRNA treatment was confirmed by 
western blotting (Fig. 10A). From the TNF- induced genes that were 
down-regulated by NPM1 knockdown as shown in the heatmap (Fig. 2D), I 
picked up and examined the expression of the cytokines CCL2 and CCL20, 
which have been reported to regulate the migration of breast cancer cells 
(45,46). Consistent with the invasion assays, p65 knockdown efficiently 
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blocked the expression of its target genes CCL2 and CCL20, but not GAPDH, 
and NPM1 knockdown also decreased the target gene expression (Fig. S5C). 
Considered together, I concluded that NPM1 and NF-κB cooperatively regulate 
the cancer progression induced by the NF-κB signaling. 
  
1-5. Discussion 
The data presented in this study suggest a working model in which NPM1 
interacts with NF-κB in the nucleus to stimulate the binding of NF-κB to target 
gene promoters. Interestingly, NPM1 itself disassociates from NF-κB once 
NF-κB binds to DNA (Fig. 7B). NPM1 interacts with the N-terminal DNA binding 
domain of p65 and competes with DNA for the binding to p65, which results in 
the release of NPM1 after p65 binds to DNA (Fig. 6). These results suggest 
that the chaperone-like function of NPM1 is required for the maximal 
transcription stimulatory activity of NF-κB. Another contribution of NPM1 on 
NF-κB mediated transcription could be explained by the result that inhibits the 
intramolecular interaction between the N- and C-terminal domains of p65 (Fig. 
7A) to allow transcriptional coactivators CBP/p300 to interact with p65-C 
terminus because the p65-N/p65-C intramolecular interaction blocks the p65-C 
binding site of CBP/p300 (38). I noted that although the expressions of some 
NF-κB target genes such as PLAU and IL-8 were greatly decreased by NPM1 
knockdown (Fig. 2E), the recruitment of NF-κB p65 to the promoters was only 
decreased to about half (Fig. 3C). Thus, it is possible that NPM1 regulates 
both the DNA binding and activator recruitment activities of the NF-κB proteins. 
The results also showed that NPM1 regulates specific NF-κB target genes 
by promoting the binding of NF-κB to those gene promoters. This specificity is 
at least dependent on the DNA sequences on the gene promoters. Because in 
vitro experiments showed that, NPM1 enhanced the binding of p65 to the 
specific DNA, although NF-κB p65 alone did not have the preference for 
binding to the κB containing DNA derived from different target gene promoters. 
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It is possible that the interaction of NPM1 may induce the conformational 
changes of p65 resulting in the sequence specificity of p65. Another possibility 
is that other NF-κB cofactor(s) might be involved in the regulation of these 
genes either by competing with NPM1 to bind to NF-κB or by compensating 
the function of NPM1 in NPM1 knockdown cells. For example, it has been 
reported that RPS3 interacts with p65 and regulates a subset of NF-κB target 
genes (22), cyclin-dependent kinase 6 interacts with p65 and is recruited to 
distinct chromatin regions of inflammatory genes (25), and telomerase binds to 
a subset of inflammatory gene promoters containing the T2G3 sequences and 
is required for efficient recruitment of p65 to these genes (24). It will be 
important to understand how these cofactors, including NPM1, cooperatively 
or independently regulate the NF-κB functions in inflammatory responses and 
cancer progression. 
NF-κB mediated transcription does not simply depend on the amount of 
NF-κB. The posttranslational modifications and co-factors, as well as the 
chromatin structure around their target genes contribute to determining the 
NF-κB activity. Precisely controlled NF-κB activity is required for normal cell 
growth and immune and inflammatory responses (47). NPM1 is broadly 
expressed in normal cells and is suggested to contribute to the maintenance of 
appropriate NF-κB activity as it was shown to regulate NF-κB mediated 
transcription in fibroblasts and macrophages which are the components of 
tumor microenvironment (Fig. 8C and 8D). In addition, NPM1 may potentially 
contribute to the oncogenic NF-κB functions in cancer cells as it regulates the 
NF-κB mediated transcription in cancer cells (Fig. 2) and its expression level is 
correlated to NF-κB activity in colon adenoma and breast cancer cell lines (Fig. 
8). The results that NPM1 regulated NF-κB mediated inflammatory genes in 
both cancer cells and normal cells like macrophages suggest the oncogenic 
role of NPM1 in both tumor cells and the tumor microenvironment through the 
regulation of NF-κB. Considering that NPM1 also shows other oncogenic 
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functions independent of NF-κB, such as regulating the activity and stability of 
p53 and ARF, cell growth, proliferation, and anti-apoptosis, it is likely that the 
expression level of NPM1 is a suitable diagnostic marker to determine the 
aggressiveness of cancer cells and also a suitable target of cancer therapy. 
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1-6. Figures and legends 
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Fig. 1 Interaction between NPM1 and NF-κB 
(A) Purified NF-κB proteins. Flag tagged p65, RelB, and c-Rel were expressed 
and purified with Flag-affinity gel, and the proteins were separated by 10% 
SDS-PAGE and visualized by CBB staining. (B) GST-pull down assays. GST 
pull-down assays using GST (lanes 4–6) or GST-NPM1 (lanes 7–9) with 
purified Flag-p65 (RelA), Flag-RelB, or c-Rel were performed. Flag-tagged 
NF-κB proteins were detected by western blotting and the GST proteins were 
visualized by CBB staining. (C) Immunoprecipitation assays. Flag-p65, 
Flag-p50, or Flag-p50/HA-p65 was expressed and the association with NPM1 
was analyzed by immunoprecipitation (IP) with anti-Flag antibody followed by 
western blotting. (D) Flag-tagged p65 (lanes 1–3) and p50 (lanes 4–6) was 
mixed with GST or GST-NPM1 and the bound proteins with the GST proteins 
were examined by western blotting with anti-Flag antibody. The membranes for 
western blotting were stained with CBB to visualize the GST proteins. (E, F) In 
vivo interaction between NPM1 and p65. The interaction between NPM1 and 
p65 was examined by in situ proximity ligation assays (PLAs). HeLa cells were 
treated with or without 20 ng/ml TNF-α for 1 h, PLAs were performed using 
primary antibodies against NPM1 and p65. The PLA signals in panel C were 
quantitatively analyzed by the image processing software Imaris. The average 
spot number per cell was calculated from randomly selected cells (n=20). Error 
bars represent ±SD, statistical significance was calculated using student’s 
t-test, and *** indicates p<0.001. (F) Localization of NPM1 in TNF-α treated 
cells.HeLa cells stably expressing EGFP-NPM1 were treated without or with 
TNF-α (20 ng/ml) for 15 min and 60 min, followed by immunofluorescence 
analysis with anti-p65 antibody, and the localization of the proteins was 
observed by a confocal microscope. Bar at the bottom indicates 10 μm. 
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Fig. 2. NPM1 regulates NF-B-dependent gene transcription 
(A) Knockdown of NPM1 in HeLa cells by siRNA treatment.  Western blotting 
confirmed the knockdown of NPM1 in HeLa cells. β-actin is a loading control. 
(B) Reporter assay. HeLa cells treated with NS or NPM1 siRNAs were 
transfected with p-κB-Luc and p-TA-RL plasmids. The cells were then 
stimulated without or with TNF-α for 3 h and subjected to luciferase assay. The 
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relative luciferase activity (fold increase) is shown. Three independent 
experiments were performed and error bars indicate ±SD. (C) Scatter plots of 
genes in HeLa cells treated with or without TNF-α (chip 1 vs chip 2). (D) 
Scatter plots of genes in HeLa cells transfected with control or NPM1 siRNA 
without TNF-α treatment (chip 1 vs chip 3). (E) Scatter plots of genes in HeLa 
cells transfected with control or NPM1 siRNA with TNF-α treatment (chip 2 vs 
chip 4). (F-I) Microarray analyses. RNAs were extracted from HeLa cells 
treated with control siRNA (chip 1 and 2) or NPM1 siRNA (chip 3 and 4) 
followed by stimulation without (chip1 and 3) or with TNF-α (chip 2 and 4), and 
subjected to microarray analyses. (F) The Venn diagram (upper panel) shows 
the coding genes induced by TNF-α treatment (chip 1 vs 2), the coding genes 
down-regulated by NPM1 knockdown in cells treated with TNF-α (chip 2 vs 4), 
and their overlapped genes. The overlapped 32 genes were subjected to gene 
ontology analysis and the list of the enriched functions is shown. Heat maps 
(G) depict the expression of the 32 overlapped genes (left) and the fold 
changes (right) between control and NPM1 knockdown cells treated with 
TNF-α (chip 2 vs 4). (H) The list of 32 genes shown in Figure 2D and fold 
changes of their expression level. (I) The Venn diagram shows the coding 
genes induced by TNF-α treatment (chip 1 vs 2), the coding genes 
up-regulated by NPM1 knockdown in cells treated with TNF-α (chip 2 vs 4), 
and their overlapped genes. The seven overlapped genes are shown.  
(J) Confirmation of the microarray data by real-time RT-PCR analyses. 
RT-PCR for the genes involved in the list of (D) was performed using RNA 
extracted from cells treated with or without siRNAs and TNF-α as indicated at 
the bottom. RT-PCR was also examined for the two genes (NR4A2 and 
DUSP5) that were up-regulated by NPM1 knockdown. 
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Fig. 3. NPM1 regulates the target gene binding of NF-κB, but not its 
nuclear translocation 
(A) Effect of NPM1 knockdown on the expression level of I-κBα. The amounts 
of I-κBα and β-actin in HeLa cells treated with control siRNA or NPM1 siRNA 
after TNF-α treatment were examined by western blotting. Time (min) after 
TNF-α treatment is shown at the bottom of the panel. (B) Localization of p65 
after TNF-α treatment in HeLa cells treated with control or NPM1 siRNA. DNA 
was counter stained by DAPI. (C) Recruitment of p65 to its target genes. HeLa 
cells transfected with siRNAs as indicated were incubated without or with 
TNF-α for 1 h, followed by ChIP assay.  The precipitated DNA amounts 
containing the promoter regions of the genes listed in Fig. 2D (TNF-α, PLAU, 
and IL-8) and those of stimulated genes (NR4A2 and DUSP5) by NPM1 
knockdown were quantitatively analyzed by q-PCR. Three independent 
experiments were performed and error bars indicates ±SD. 
Figure3 
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Figure 4 
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Fig. 4. NPM1 enhances the DNA binding activity of NF-κB 
(A) Purified proteins. His-tagged NPM1 and the NF-κB proteins purified with 
Flag-tag antibody were separated by SDS-PAGE and visualized by CBB 
staining. (B) EMSA with purified proteins. Purified recombinant NF-κB proteins 
(20 ng/sample) were analyzed by EMSA with a [32P]-labeled, double-stranded 
wild-type (WT) or mutant (mut) κB oligonucleotides (300 fmole/sample). 
Antibodies against p65, Flag-tag, or HA-tag were added in the mixture as 
shown in lanes 4 and 7–9. (C) Effect of NPM1 on the DNA binding activity of 
the NF-B proteins. Flag-p65 and Flag-p50/HA-p65 (20 ng, lane 2–5 and 6–9, 
respectively) were incubated with increasing amounts of His-NPM1 (0, 50, 100, 
and 200 ng), followed by EMSA with [32P]-labeled probe (200 fmole/sample). 
The NPM1 alone (200 ng) were also incubated with the same probe (lane 1). 
(D) Supershift analysis with NPM1 antibody. Flag-p65 and Flag-p50/HA-p65 
(20 ng, lanes 2–5 and 6–9, respectively) were incubated without or with 
His-NPM1 (200 ng) and indicated antibodies, followed by EMSA. The DNA 
bands bound by the p65–p65, p65–p50 and p50–p50 complexes, free probes, 
and supershifted bands are indicated by filled arrowheads, blank arrowheads, 
and asterisks, respectively (B–D). (E) Chromatin immunoprecipitation assay. 
HeLa cells were treated with TNF-α (20 ng/ml) for indicated time periods and 
then subjected to ChIP assays with control Ig, ant-p65, and anti-NPM1 
antibodies. The ribosomal RNA gene coding region (rDNA) and the promoter 
regions of PLAU and IL-8 genes were analyzed by qPCR. 
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Figure 5 
 
 
Fig. 5. The domain mapping of NPM1 and p65 required for their 
interaction 
(A) Diagram of the splicing variants and truncation mutants of NPM1. Black 
boxes indicate oligomerization domain, light gray boxes at the central regions 
are acidic regions, dark gray indicates the C-terminal globular domain. (B) 
GST-pull down assay. GST or GST fusion proteins were incubated with purified 
Flag-p65 (500 ng/sample) and bound proteins were analyzed by SDS-PAGE, 
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followed by CBB staining for GST proteins (bottom panels) or western blotting 
with Flag antibody (top panels). (C) Diagram of the mutants of p65. The 
N-terminal DNA binding domain, dimerization domain, and the activation 
domain are shown by black, light gray, and dark gray boxes, respectively. (D) 
Immunoprecipitation analysis of the Flag-tagged p65 mutant proteins. 
Flag-tagged wild type and truncated p65 proteins were transiently expressed in 
293T cells and immunoprecipitated with anti-Flag antibody. Input and 
immunoprecipitated proteins were analyzed by western blotting with anti-Flag 
and -NPM1 antibodies. 
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Figure 6 
 
 
Fig. 6. The chaperone-like function of NPM1 enhances the binding of p65 
to specific sequences 
(A) Purified proteins. His-p65-N and His-p65-C were separated by SDS-PAGE 
and visualized by CBB staining. (B) Effect of NPM1 on the DNA binding activity 
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of p65-N. His-p65-N (40 ng, lane 1–5) were incubated with increasing amounts 
of His-NPM1 (0, 100, 200, 400 and 800 ng), and EMSA was performed. DNA 
was visualized by GelRed staining. (C) NPM1 and DNA complete for p65-N 
binding. His-NPM1 (60 pmole, lanes 2–8) was incubated with increasing 
amounts of His-p65-N (lanes 2–5, 0, 25, 50, 100 pmole, lanes 6–9, 100 pmole), 
then incubated without (lanes 1–5) or with increasing amounts of the κB DNA 
(for lanes 6–8, 40, 80, and 160 pmole, respectively). Lane 1 and 9 indicate 
His-p65-N alone (100 pmole) and the mixture of His-p65-N (100 pmole) and 
the κB DNA (160 pmole), respectively. The complexes were separated by 
native PAGE and visualized by CBB staining. Positions of free NPM1 are 
shown at the left side of the panel and the accumulated free NPM1 is also 
indicated by asterisks at the right side of the lanes. (D) The binding of p65-N to 
different DNA probes. Three κB DNA fragments (2 pmole) derived from Ig, IL-8, 
and NR4A2 genes as shown at the right of the panel were incubated with 
increasing amounts of His-p65-N protein (0, 0.5, 1, 2 pmole, lanes 1-4, 5-8, 
9-12, respectively), separated by native PAGE, and visualized by GelRed 
staining. The κB consensus sequences are indicated by capital letters. (E) 
NPM1 enhances the binding of p65-N to specific κB sites. The κB DNA 
fragments as in (D) were mixed with His-p65-N protein (0.5 pmole) 
pre-incubated with increasing amounts of His-NPM1 (0, 100, 200, 400, lanes 
2-5, lanes 7-10, lanes 12-15), separated by native PAGE, and visualized by 
GelRed staining. Lanes 1, 6 and 11 indicate the kB DNA fragments without 
p65-N or NPM1. The intensity of the bands for p65-N-DNA complex were 
quantitatively analyzed and shown at the right graph. The experiments were 
repeated 5 times and error bars indicate ±SD. Blank and filled arrowheads in D 
and E show free DNA probes and the p65-N-DNA complexes, respectively. 
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Figure 7 
 
 
 
Fig. 7. NPM1 abrogates the intramolecular interaction of p65 
(A) NPM1 abrogates the interaction between p65-N and p65-C. His-p65-C 
(lanes 2–8, 12 pmole) was incubated with increasing amounts of His-p65-N 
(lanes 2–5, 0, 9, 27, 54 pmole, and lanes 6–8, 54 pmole) and His-NPM1 (lanes 
2–5, 0 pmol, lanes 6–8, 20, 40, 80 pmole), lane 1 indicates 54 pmole of 
His-p65-N alone, lane 9 indicates 80 pmole of His-NPM1 incubated with 54 
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pmole of His-p65-N. Proteins were separated by native PAGE and visualized 
by silver staining. (B) A working model of NF-κB-mediated transcription 
regulated by NPM1. Upon stimulation, the NF-κB is translocated to the nucleus 
where it associates with NPM1. The association of NPM1 enhances the DNA 
binding activity of NF-κB and abrogates the intramolecular interaction of p65. 
NPM1 releases NF-κB upon its binding to target DNA. 
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Figure 8 
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Fig. 8. Functional intersection between NPM1 and NF-κB signaling 
(A) Expression and localization of NPM1 and p65 in inflammatory colon in 
Apcmin/+ mice. Hematoxylin and eosin (HE) staining, and 
immunohistochemistry with anti-NPM1 and anti-p65 antibodies are shown as 
indicated. “N” and “Ad” represent normal and adenoma, respectively. Scale 
bars indicate 50 μm. (B) Western blotting of p53-/- and p53-/-NPM1-/- MEFs with 
anti-NPM1 and anti-β actin. (C) The NF-κB-dependent reporter activity in 
MEFs. p53-/- and p53-/-NPM1-/- MEFs transfected with reporter plasmids for 16 
h, stimulated without or with TNF-α (20 ng/ml) or LPS (1 g/ml) for 3 h, and 
examined for luciferase activity. The relative NF-κB-driven luciferase activity 
(fold increase) is shown. Three independent experiments were performed and 
error bars are ± SD. (D) Western blotting of mouse peritoneal macrophages. 
Mouse peritoneal macrophages were transfected with NS or NPM1 siRNA for 
72 h, followed by treatment with or without LPS (1 μg/ml) for 2 h. The extracts 
were subjected to western blotting with anti-NPM1 and anti-β actin antibodies. 
(E) Expression of cytokine genes in macrophages. Total RNAs were extracted 
from cells as in (D) and the expressions of cytokines (TNF-α, IL-1β, IL-6, IFN-β) 
and GAPDH were analyzed by RT-qPCR. (F) Expression of NPM1 in breast 
cancer cell lines. Cell extracts (2 and 4 μg of proteins for top and middle panels, 
respectively) from BT-20, MDA-MB-157, MDA-MB-231, or MDA-MB-436 cells 
were separated by 10% SDS-PAGE and the expression of p65, β-actin, and 
NPM1 was examined by western blotting (top and middle panels). Total RNA 
was extracted from the cells and the expression of NPM1 and β-actin mRNA 
was quantitatively analyzed. The amount of NPM1 mRNA was normalized by 
that of β-actin and shown in bottom graph. (G) Relationship between the 
NF-κB activity and NPM1 expression level. The constitutive NF-κB activity 
obtained from previously published data (42) was plotted as a function of the 
NPM1 mRNA level shown in (F). (H) Invasion activity of MDA-MB-231 cells. 
MDA-MB-231 cells were transfected with NS, NPM1, p65, or NPM1 and p65 
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siRNAs for 48 h, seeded in transwells coated with Matrigel, and treated without 
or with TNF-α for 16 h. Representative images of the bottom surface are 
shown in Fig. S5B. Cell number detected at the bottom surface of control 
siRNA-treated and non-stimulated cells was set as 1.0, and relative cell 
numbers were quantitatively analyzed. Cell numbers were averages of 4 
random microscopic fields from 3 independent experiments. *** indicates p 
<0.001.           
 
 
Fig. 9 
 
Fig. 9. Expression of NPM1 in breast cancer cell lines  
Expression of NPM1 in commonly used 51 breast cancer cell lines were 
examined by the GOBO database (http://co.bmc.lu.se/gobo/gsa.pl). Average 
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NPM1 expression in 12 Basal A (red), 14 Basal B (gray), and 25 Luminal (blue) 
cell lines are indicated as box plot (A) and the NPM1 expression in individual 
cells are shown in (B). 
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Fig. 10 
 
Fig. 10. NF-kB mediated invasion activity of MDA-MB-231 cells regulated 
by NPM1  
(A) Western blotting. MDA-MB-231 cells were transfected with siRNAs as 
indicated at the top of the gel and the expression level of proteins was 
analyzed by western blotting. (B) Invasion activity of MDA-MB-231 cells. 
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MDA-MB-231 cells were transfected with NS, NPM1, p65, or NPM1 and p65 
siRNAs for 48 h, seeded in transwells coated with Matrigel, and treated without 
or with TNF-α for 16 h. Representative images of the bottom surface are 
shown. (C) RT-qPCR. The cells prepared as in (A) were treated without or with 
TNF-α for 12 hrs, and RNAs were extracted from cells prepared as in A and 
analyzed by RT-qPCR. The experiments were independently repeated three 
times and error bars indicate ± SD. 
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1-7. Table for primers 
 
Table 1. Primer sets for RT-PCR 
 
NR4A2 F GTATGGGTCCTCGCCTCAAG 
NR4A2 R AGCCTGTGCTGTAGTTGTCC 
DUSP5 F ACAGCCCTGCTGAATGTCTC 
DUSP5 R GGAGCTAATGTCAGCCGTGT 
CCL20 F GAATCAGAAGCAGCAAGCAAC 
CCL20 R TTGCGCACACAGACAACTTTTT 
CCL2 F GATCTCAGTGCAGAGGCTCG 
CCL2 R TTTGCTTGTCCAGGTGGTCC 
PLAU F GACTCCAAAGGCAGCAATGA 
PLAU R TGCTGCCCTCCGAATTTCTT 
SELE F CCGAGCGAGGCTACATGAAT 
SELE R GCCACATTGGAGCCTTTTGG 
RND1 F CAGCGACTCGGATGCAGTAT 
RND1 R CTGTCTTGCAGCCAATGAGC 
IL-8 F TAGCAAAATTGAGGCCAAGG 
IL-8 R AAACCAAGGCACAGTGGAAC 
TNF-a F TCCTTCAGACACCCTCAACC 
TNF-a R AGGCCCCAGTTTGAATTCTT 
IkBa F CTCCGAGACTTTCGAGGAAATAC 
IkBa R GCCATTGTAGTTGGTAGCCTTCA 
GAPDH F CCACATCGCTCAGACACCAT 
GAPDH R GCGCCCAATACGACCAAA 
hCXCR4 F TCCATTCCTTTGCCTCTTTTGC 
hCXCR4 R ACGGAAACAGGGTTCCTTCAT 
Mouse TNF-a F ACA AGGCTGCCCCGACTA C 
Mouse TNF-a R TGGAAGACTCCTCCCAGGTATATG 
Mouse IL-6 F CCCAATTTCCAATGCTCTCC 
Mouse IL-6 R TCCACAAACTGATATGCTTAGG 
Mouse IFN-β-F CAGCTCCAAGAAAGGACGAAC 
Mouse IFN-β-R GGCAGTGTAACTCTTCTGCAT 
Mouse IL-1 β F CTTCAAATCTCACAGCAGCACATC 
Mouse IL-1 β R CCACGGGAAAGACACAGGTAG 
Mouse CCL2 F CCCCACTCACCTGCTGCTAC 
Mouse CCL2 R CCTGCTGCTGGTGATTCTCTT 
Mouse GADPH F ACCCAGAAGACTGTGGATGG 
Mouse GADPH R CACATTGGGGGTAGGAACAC 
 
 
50 
 
 
 
Table 2. Primer sequences for ChIP-PCR assays 
 
DUSP5 F CTTATATGGGCAGCCGCGT 
DUSP5 R CTAGAAGCCGGGGATTCCG 
NR4A2 F CTCTGAGCGTCTCGTGTCATG 
NR4A2 R CCCCCTTAGCGGAAGAGC 
IL-8 F ATCAGTTGCAAATCGTGGA 
IL-8 R TGCCTTATGGAGTGCTCCGGTG 
TNF-a F CCACAGCAATGGGTAGGAGAATG 
TNF-a R TTCATGAAGCTCTCACTTCTCAG 
PLAU F AGCAATCAGCATGACAGCCT 
PLAU R CTGCAGCCTGAGGACTTACC 
rDNA #3 F CTCTTAGCGGTGGATCACTCG 
rDNA#3 R GCTAGCTGCGTTCTTCATCGA 
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Chapter 2: Functional characterization and efficient 
detection of Nucleophosmin/NPM1 oligomers 
 
 
2-1. Abstract 
NPM1/nucleophosmin is a multifunctional phosphoprotein that has been 
implicated in oncogenesis. Plenty of observations have suggested that 
changes of the oligomer formation of NPM1 could influence its biological 
functions, especially its oncogenic functions, although the effect of oligomer 
formation on the biochemical activities of NPM1 is not well understood. This 
highlights the importance of monitoring the cellular oligomeric state of NPM1 
under different conditions or stimuli for understanding its oncogenic functions. 
In this study, I demonstrate that oligomerization of NPM1 is necessary for its 
histone chaperone activity in vitro. Furthermore, to monitor the cellular 
oligomer formation of NPM1, I utilized the split synthetic Renilla luciferase 
protein fragment-assisted complementation (SRL-PFAC) bioluminescence and 
observed the change of NPM1 oligomer levels upon mitotic synchronization, 
TNF-α treatment, and serum starvation. This study provides a promising 
method for systematic characterization of NPM1 oligomer formation changes, 
and for screening of NPM1 oligomerization inhibitors for cancer therapy. 
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2-2. Introduction 
NPM1/nucleophosmin/B23 was first identified as a phosphoprotein 
expressed at high levels in the granular region of the nucleolus [1]. It mainly 
resides in the nucleolus but continuously shuttles between the nucleolus, the 
nucleoplasm, and the cytoplasm [2]. It has been implicated in multiple cellular 
functions, including ribosome biogenesis [3], centrosome duplication [4], 
molecular chaperoning [5], chromatin regulation [6], and regulation of the ARF, 
HDM2, and p53 tumor suppressor pathway [7-9]. NPM1 directly binds to 
histones and mediates nucleosome assembly in vitro as a histone chaperone 
[6]. In addition, NPM1 binds directly to RNAs and the RNA binding activity of 
NPM1 is suggested to be required for its nucleolar localization [10]. Importantly, 
the genetic alterations of the NPM1 gene have been detected in hematological 
malignancies, and NPM1 overexpression was observed in various solid tumors. 
In addition to the overexpression of NPM1 protein and mutation of NPM1 gene, 
NPM1 oligomerization has been suggested to maintain its oncogenic functions.  
All in all, NPM1 has been proposed as a cancer marker and potential 
therapeutic target for cancer therapy [11]. 
NPM1 belongs to the nucleoplasmin protein family which includes NPM2 
and NPM3. All these proteins share a conserved N-terminal core domain that 
is required for oligomerization [12]. Various observations have suggested that 
the oligomeric state of NPM1 is important for its biological functions, especially 
its functions in cancer. For example, inhibition of NPM1 oligomerization by a 
small molecule [13] or an RNA aptamer [14] resulted in mislocalization of 
NPM1 in the nucleoplasm, induction of p53-dependent apoptosis, increased 
sensitivity to DNA damage in human cancer cells; IKKα promotes the 
oligomerization of NPM1 to induce the localization of NPM1 to centrosome, 
thereby maintains genome integrity [15]; cleavage of the NPM1 protein by the 
cytotoxic lymphocyte granule protease granzyme B in hepatoma but not 
normal liver cells stabilizes the oligomeric form of NPM1 to enhance the 
localization of NPM1 to the nucleolus [16]. The oligomerization of the N 
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terminal core domain of NPM1 is regulated by both posttranslational 
modification and protein binding. Phosphorylation in the N terminus of NPM1 
destabilizes the oligomeric form of NPM1, while binding to target proteins 
containing R-rich motifs stabilizes the oligomeric structure, counteracting the 
destabilization associated with phosphorylation [16]. Given the importance of 
NPM1 oligomerization for its biological functions, it is important to monitor the 
changes of cellular NPM1 oligomeric state under different conditions or stimuli 
to understand its functions.  
In this study, I first demonstrated that oligomerization of NPM1 is necessary 
for its histone chaperone activity, but dispensable for its binding to histones or 
RNA in vitro. To systematically monitor the cellular oligomer formation of NPM1, 
I utilized the split synthetic Renilla luciferase protein fragment-assisted 
complementation (SRL-PFAC) and examined the change of NPM1 oligomer 
levels under several cell culture conditions. This study provides a promising 
method for systematic characterization of NPM1 oligomer formation changes, 
and for screening of NPM1 oligomerization inhibitors. 
 
 
 
 
 
 
 
 
 
2-3. Materials and methods 
2-3-1. Cell culture, transfection, reporter assay, and reagents 
HeLa and 293T cells were cultured in DMEM supplemented with 10% 
heat-inactivated fetal bovine serum (FBS) at 37ºC with 5% CO2. To establish 
stable cell lines, HeLa cells were co-transfected with 
pcDNA3.1-Flag-N-RL-NPM1 and pcDNA3.1-Flag-C-RL-NPM1 or 
pcDNA3.1-Flag-N-RL-NPM1 and pcDNA3.1-Flag-C-RL using Gene Juice 
58 
 
(Novagen) according to the manufacturer's instructions. Neomycin-resistant 
cells were selected by 0.1 mg/ml G418.  
Luciferase assay was performed using Renilla Luciferase Assay System kit 
(Promega Corporation, USA) according to the manufacturer’s instructions. For 
mitotic cell preparation, cells were treated with 100 ng/ml Nocodazole for 18 h 
and mitotic cells were collected by gentle shaking of the dishes. 
Antibodies used were NPM1 (FC-61991, Thermo Fisher Scientific), 
Flag-tag (M2, Sigma Aldrich), p65 (ab7970, Abcam) and β-actin (sc-47778, 
Santa Cruz Biotechnology). Recombinant human TNF-α (PEPROTECH) was 
commercially available. 
 
2-3-2. Plasmid construction 
To construct pET14b-NPM1-LG and -SG, cDNA fragments containing 
mutations were amplified by two-step PCR. First PCR was conducted using 
primers; 5’-TAATACGACTCACTATAGG-3’ and 
5’-AATATGCACTGGCCCTGAGGCACACTTGGCCCTTA-3’, and 
5’-CCACCAGTGGTCTTAAGGGCCAAGTGTGCCTCAGG-3’ and 
5’-GCTAGTTATTGCTCAGCGG-3’ for pET14b-NPM1-LG, and 
5’-TAATACGACTCACTATAGG-3’ and 
5’-AATATGCACTGGAGCAGCACCACACTTCAACCTTA-3’, and 
5’-TTGAAGTGTGGTGCTGCTCCAGTGCATATTAGTGG-3’ and 
5’-GCTAGTTATTGCTCAGCGG-3’ for pET14b-NPM1-SG with pET14b-NPM1 
as a template.  These two fragments were purified and used as templates of 
second PCR and the full-length cDNA fragments were amplified using T7 
promoter and terminator primers. The cDNA fragments were digested with Nde 
I and BamH I and inserted into the same sites of pET14b. For constructing 
pEGFP-Flag-NPM1-LG and -SG, pET14b-NPM1-LG and -SG were digested 
with Nde I and Hind III and cloned into the same sites of pBS-Flag. The 
pBS-Flag plasmids were digested with BamH I and then the cDNA for the 
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Flag-tagged proteins were cloned into BamH I digested pEGFP-C1. 
For the split synthetic Renilla luciferase (hRL) fusion plasmids [17], the 
N-terminal (N-RL, a.a. 1-229) and C-terminal (C-RL, a.a. 230-311) synthetic 
Renilla luciferase gene were PCR-amplified using the primers containing the 
linker DNA sequences GGTGGCGGAGGGAGCGGTGGCGGAGGGAGC in 
the reverse primers. The N-RL and C-RL fragments were first PCR-amplified 
using phRL-TK (Promega) as a template with primers 
5’-AGCTAGCATATGAATGGCTTCCAAGGTGTACGA-3’ and 
5’-ATGCGGATCCGCTCCCTCCGCCACCGCTCCCTCCGCCACCGCCTCCC
TTAACGAGAGGGA-3’ for N-RL, 
5’-AGCTAGCATATGAAAGCCCGACGTCGTCCAGATT-3’ and 
5’-ATGCGGATCCGCTCCCTCCGCCACCGCTCCCTCCGCCACCCTGCTCG
TTCTTCAGCACGC-3’ for C-RL. All the amplified fragments were digested 
with Nde I and BamH I and subcloned into the same sites of pET14b to 
construct plasmids pET14b-N-RL and pET14b-C-RL plasmids. The cDNA for 
NPM1 was inserted to the BamH I site of pET14b-N-RL and pET14b-C-RL to 
construct pET14b-N-RL-NPM1 and pET14b-C-RL-NPM1. To construct 
pcDNA3.1-Flag-N-RL-NPM1, pcDNA3.1-Flag-C-RL-NPM1, and 
pcDNA3.1-Flag-C-RL, the cDNAs for N-RL-NPM1, C-RL-NPM1, and C-RL 
were PCR-amplified using pET14b vectors as templates with primers 
5’-AGCTAGGAATTCAATGGCTTCCAAGGTGTACGA-3’                 
and 5’-AGCTTCTAGATTAAAGAGACTTCCTCCACTGCCA-3’, 5’- 
AGCTAGGAATTCAAAGCCCGACGTCGTCCAGATT-3’ and  
5’-AGCTTCTAGATTAAAGAGACTTCCTCCACTGCCA-3’, and 
5’-AGCTAGGAATTCAAAGCCCGACGTCGTCCAGATT-3’ and 
5’-ATGCTCTAGATTAGCTCCCTCCGCCACCGCTCCC-3’, respectively. All the 
amplified fragments were digested with EcoR I and Xba I, and subcloned into 
the same sites of pcDNA3.1-Flag vector. All the amplified sequences were 
verified by DNA sequencing. 
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2-3-3. Binding assays 
For immunoprecipitation assay, cells were lysed and sonicated in buffer A 
containing 150 mM NaCl and the supernatants were collected and mixed with 
ANTI-FLAG® M2 affinity gel (SIGMA-ALDRICH) followed by incubation at 4oC 
for 1 h. The Flag-tagged proteins were eluted with FLAG peptide 
(SIGMA-ALDRICH) after extensive washing and analyzed by SDS-PAGE 
followed by western blotting.  
For GST-pull down assay, glutathione-sepharose beads immobilized GST 
proteins were mixed with 1 -H2B or H3-H4 histone complexes in 
buffer A containing 100 mM NaCl and incubated at 4ºC for 2 h followed by 
extensive washing with the same buffer. Proteins were eluted from the beads 
with a SDS sample buffer, separated by SDS-PAGE, and visualized by CBB 
staining. Recombinant proteins and core histones were purified as described 
previously [18, 19].  
 
2-3-4. Immunofluorescence 
HeLa cells were treated without or with TNF-α (20 ng/ml) for 3 h, cells on 
cover slips were fixed with 3% paraformardehyde in PBS, and permeabilized in 
PBS containing 0.5% Triton X-100. The cells on coverslips were then 
incubated with p65 antibody diluted with PBS containing 0.5% non-fat dry milk. 
Localization of proteins was visualized with secondary antibodies conjugating 
with AlexaFluor dyes (Molecular Probes). During final wash with PBS 
containing 0.1% Triton X-100, DAPI DNA staining dye was added and 
incubated for 15 min at room temperature. Images were observed under 
confocal microscope (LSM EXCITER; Carl Zeiss Microimaging, Inc.). 
 
2-3-5. Nucleosome assembly assay and RNA binding assay 
Purified recombinant core histones (30 ng) were incubated with increased 
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amount of His-NPM1, His-NPM1-SG or His-NPM1-LG at room temperature for 
20 min, followed by additional incubation with the 196 bp-long 5S rDNA 
fragment (10 ng) at room temperature for 30 min. Samples were resolved on a 
6% native PAGE in 0.5xTBE buffer. DNA was visualized by GelRed staining. 
Supercoiling assay was performed as described previously [6] using 
pCAGGS relaxed by incubation with topoisomerase I (TAKARA). Filter binding 
assay and sucrose density gradient assay were performed as described 
previously [18]. Total RNAs extracted from HeLa cells were labeled with 
polynucleotide kinase (TOYOBO) and [ᵞ-32P]ATP and used for filter binding 
assays. 
 
 
  
62 
 
2-4. Results  
2-4-1. Biochemical characterization of NPM1 oligomers 
To examine the effect of oligomerization of NPM1 on its biochemical 
activities, I have constructed NPM1 mutants that show low oligomerization 
activity. Previous study demonstrated that the mutations in amino acids L102, 
G105, S106, and G107 located in the GSGP loop in the oligomerization 
domain of NPM1 destabilize the oligomerization [20]. When the wild type 
NPM1 tagged with EGFP-Flag was expressed and immunoprecipitated, the 
endogenous NPM1 protein was co-immunoprecipitated (Fig. 1A, lanes 5 and 
6), indicating the oligomerization of the exogenous and endogenous NPM1 
proteins. On the other hand, NPM1-LG (L102A/G105A) and NPM1-SG 
(S106A/G107A) tagged with EGFP-Flag were immunoprecipitated with the 
endogenous NPM1 inefficiently (lanes 7 and 8). Therefore, these mutations 
were ensured to inhibit the oligomerization of NPM1. 
To test the function of these oligomer mutants, the wild type and mutant 
proteins were expressed in E. coli and purified (Fig. 1C), and their histone 
chaperone activities and RNA binding activities were examined in vitro. I first 
examined the histone binding activities of NPM1 wild type and mutants by 
GST-pull down assays. GST-tagged wild type NPM1, but not GST alone, 
efficiently pulled down both the core histones H2A-H2B and H3-H4 complexes 
(Fig. 1B, lanes 1, 2, 5, and 6). Similarly, both GST-NPM1-SG and 
GST-NPM1-LG efficiently bound to core histones as did wild type (lanes 3, 4, 7, 
and 8), indicating that the oligomerization was dispensable for the histone 
binding activity of NPM1. Next, the nucleosome assembly activities of the 
mutants were examined using purified core histones and the 196 bp-long 5S 
rDNA fragment (Fig. 1D). When core histones were directly mixed with naked 
DNA, histones randomly bound to DNA and that the complex could not enter 
native PAGE (lanes 2, 6, and 10). However, when core histones were 
preincubated with wild type NPM1 and then DNA was added, the bands 
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migrated slower than naked DNA appeared. These bands were previously 
shown to correspond to nucleosome core particle [19], suggesting that wild 
type NPM1 binds to core histones and transfer them to naked DNA to 
assemble a nucleosome core particle. On the other hand, the activities of 
NPM1-LG and NPM1-SG were much less than that of wild type (lanes 7–9 and 
11–13). To further confirm the activity of the oligomer mutant proteins, 
supercoiling assay was performed using purified histones and relaxed circular 
plasmid DNA. When nucleosome structure is formed on plasmid in the 
presence of topoisomerase I, negative supercoil is introduced in the plasmid 
DNA (Form II), which migrates faster than relaxed circular DNA (Form I). When 
core histones alone were mixed with plasmid DNA, supercoil was not 
introduced. When core histones preincubated with increasing amounts of 
NPM1 were mixed with plasmid, Form II plasmid DNA was increased with 
increasing amount of NPM1, suggesting that NPM1 mediates efficient 
nucleosome assembly. On the other hand, the nucleosome assembly activities 
of NPM1-LG and NPM1-SG were not detected by supercoiling assay. These 
results indicate that the oligomerization of NPM1 is dispensable for histone 
binding but essential for the nucleosome assembly activity in vitro. 
I next examined the RNA binding activity of NPM1 in vitro. NPM1 binds to 
RNA through the C-terminal globular domain (Fig. 2A). The RNA binding 
activity of the NPM1 proteins were examined by filter binding assay using 
[32P]-labeled RNAs. Wild type NPM1 bound to RNAs in a dose-dependent 
manner and labeled RNA was retained on the membrane (Fig. 2B). NPM1-LG 
also bound to RNA with similar efficiency with wild type NPM1, suggesting that 
the oligomerization state of NPM1 did not strongly affect its RNA binding 
activity in vitro. I have previously shown that NPM1 binds to ribosomal RNAs 
and shows binding preference to 28S rRNAs [18]. To determine whether the 
oligomerization of NPM1 affects the RNA biding preference, sucrose density 
gradient assays were performed (Fig. 2C). Wild type NPM1 was 
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co-fractionated preferentially with 28S rRNA, whereas B23.2, a splicing variant 
of NPM1, lacking the RNA binding domain was recovered in top fractions. I 
demonstrated that NPM1-LG was co-fractionated preferentially with 28S rRNA 
as did wild type NPM1. These results indicated that the oligomerization of 
NPM1 is dispensable for the RNA binding activity in vitro. 
 
2-4-2. Establishment of the detection system of NPM1 oligomers 
Given the reported importance of NPM1 oligomerization for its biological 
functions and the different biochemical activities between the NPM1 monomer 
and oligomers, I next aimed to establish the detection system of the NPM1 
oligomers. I applied the split synthetic Renilla luciferase (RL) protein 
fragment-assisted complementation (SRL-PFAC) bioluminescence system [17] 
to detect the NPM1 oligomers. NPM1 was fused to the N-terminal RL (N-RL, 
a.a. 1–229) and C-terminal RL (C-RL, a.a. 230–311) proteins through a 
(Gly4Ser)2 peptide linker (Fig. 3A). The oligomerization of NPM1 will bring 
N-RL and C-RL in close proximity and lead to complementation of the RL 
enzyme activity. I first tested this system by transiently co-transfection of 
N-RL-NPM1 with C-RL-NPM1 or C-RL in 293T cells and reporter assay was 
performed (Figs. 3B and C). Cells transiently expressing N-RL-NPM1 and 
C-RL-NPM1 showed dramatically higher luciferase activity than that in control 
cells expressing N-RL-NPM1 and C-RL, indicating that N-RL-NPM1 formed an 
oligomer with C-RL-NPM1 but not C-RL in the cells. To systematically study 
the oligomerization of NPM1 in the cells, I established HeLa cell lines stably 
expressing N-RL-NPM1 and C-RL-NPM1 or N-RL-NPM1 and C-RL (Fig. 3D). 
The luciferase activity of the cell line expressing N-RL-NPM1 and C-RL-NPM1 
showed significantly higher luciferase activity than that of the control cell line 
expressing N-RL-NPM1 and C-RL, and was increased in a cell number 
dependent manner, indicating that the cell lines were successfully established 
and could be used for further study of NPM1 oligomerization in the cells. 
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2-4-3. Detection of cellular NPM1 oligomerization levels upon various stimuli 
I first applied this assay system for the detection of NPM1 oligomerization 
state in TNF-α treated cells, because oligomerization of NPM1 is promoted by 
the phosphorylation at Ser125 by IKKα that is activated by TNF-α stimulation 
[15]. Upon TNF-α treatment, the p65 subunit of Nuclear Factor-B was 
translocated into the nucleus (Fig. 4A), indicating the activation of IKKα by 
TNF-α in HeLa cells. Upon TNF-α treatment, the luciferase activity in the cells 
expressing N-RL-NPM1 and C-RL-NPM1 was increased in a time-dependent 
manner, whereas that in cells expression N-RL-NPM1 and C-RL was 
unchanged, indicating that TNF-α treatment enhanced the oligomerization of 
NPM1. Given that the oligomer formation of NPM1 was affected by the 
phosphorylation at the site (Ser125) outside of the oligomerization domain 
upon TNF-α treatment, it was speculated that the phosphorylation at the 
unstructured region affect the oligomerization state of NPM1. To test this 
speculation, I analyzed the NPM1 oligomerization state during the cell cycle. 
NPM1 is phosphorylated at sites outside of the oligomerization domain by 
mitotic kinases [10, 21, 22]. The cells were synchronized at mitosis by 
nocodazole treatment (Figs. 4C and D) or at G0/G1 phase by serum starvation 
(Figs. 4E and F), and the luciferase activity of the cells was examined. The 
same number of asynchronous and mitotic cells was collected for western 
blotting and luciferase assays. The expression of cyclin B in mitotic cells was 
much stronger than that in asynchronous cells, whereas the expression of 
N-RL-NPM1 and C-RL-NPM1 was not changed (Figs. 4C and E). Interestingly, 
the luciferase activity in mitotic cells showed significantly higher activity than 
that in asynchronous cells (Fig. 4D). I also found that the luciferase activity was 
decreased upon serum starvation in (Fig. 4F), indicating that the NPM1 
oligomers was decreased upon serum starvation. These results indicate that 
NPM1 oligomerization state is changed during the cell cycle. In addition, the 
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assay system using the SRL-PFAC is demonstrated to be a useful tool to 
monitor the NPM1 oligomerization state in the cells. 
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2-5. Figures and legends 
Figure 1 
 
 
Fig.1 Histone chaperone activity of NPM1 wild type and oligomer mutants 
A. Immunoprecipitation. GFP-Flag (GF), GFP-Flag-B23.1-Wt, -LG, or -SG was 
transiently expressed in 293T cells, the GFP-Flag-tagged proteins were 
immunoprecipitated with Anti-FLAG M2 Affinity Gel, and input and 
immunoprecipitated proteins were analyzed by SDS-PAGE followed by 
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western blotting using anti-NPM1 antibody. B. GST-pull down assay.  Purified 
GST, GST-NPM1, -SG, and -LG were mixed with either recombinant H2A-H2B 
(lanes 1–4) or H3-H4 (lanes 5–8) complexes and GST-pull down assays were 
performed. The proteins were analyzed by 15% SDS-PAGE and visualized by 
Coomassie Brilliant Blue (CBB) staining. Inputs indicate recombinant histone 
proteins used for the assays. Lane M indicates molecular weight markers. C. 
Purified His-tagged NPM1 proteins.  Purified His-tagged NPM1 wild type (wt), 
-SG, and -LG were separated by 10% SDS-PAGE and visualized by CBB 
staining. D. Histone transfer assay. Core histones (30 ng) were mixed with 
increasing amounts of His-tagged proteins (150, 300, and 600 ng), and then 
196 bp-long DNA was added and further incubated. The complexes were 
loaded on 6% native PAGE and DNA was visualized by Gel Red staining. 
Positions of free DNA and nucleosome core particle (NCP) are indicated at the 
left side of the panel. E. Supercoiling assay.  Increasing amounts of 
His-NPM1 (lanes 2–5; 150, 300, 600, and 1,200 ng), His-NPM1-SG and 
His-NPM1-LG (lanes 6–8 and 9–11; 300, 600, and 1,200 ng) mixed with core 
histones (200 ng) were incubated with relaxed plasmid DNA (200 ng) at 37oC 
for 50 min in the presence of DNA topoisomerase I. Purified plasmid DNA was 
separated on 1% agarose gel and visualized by staining with Gel Red. 
Positions of relaxed (Form I) and supercoiled (Form II) plasmid DNA are shown 
at the left side of the panel. 
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Figure 2 
 
 
Fig. 2. Effect of NPM1 oligomerization on its RNA binding activity 
A. Schematic representation of NPM1 and its mutants. Central acidic regions 
and the C-terminal RNA binding domain are shown with right gray and black, 
respectively. B. Filter binding assay. [32P]-labeled RNA was incubated alone or 
with increasing amount of GST, GST-NPM1, or GST-NPM1-LG (50, 100, 200, 
and 400 ng). The amount of RNA remained on the nitrocellulose membrane 
were measured and the relative amount of RNA was plotted in the graph. B. 
Sucrose density gradient centrifugation assays. His-tagged NPM1 proteins (5 
μg) were incubated with total RNA (10 μg) purified from HeLa cells at room 
temperature for 30 min and separated on 15%–45% sucrose gradient. The 
proteins in each fraction were analyzed by SDS-PAGE followed by silver 
staining.  RNAs in each fraction were purified, separated on 1% denature 
agarose gel, and visualized by staining with GelRed.  RNA data shown in the 
top panel is for NPM1 wild type. 
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Figure 3
 
 
Fig. 3 Detection of the NPM1 oligomers by the split synthetic Renilla 
luciferase (RL) fragment-assisted complementation 
A. Schematic diagram for the chimeric proteins. NPM1 was fused to the N-RL 
(amino acids 1-229) and C-RL (amino acids 230-311) portion of the RL through 
an (G4S)2 peptide linker. B, C. Detection of NPM1 oligomer by SRL-PFAC 
using transiently transfected cells. N-RL-NPM1 and C-RL-NPM1, or 
N-RL-NPM1 and C-RL were transiently expressed in HeLa cells and the 
expression of the proteins were examined by western blotting with anti-NPM1 
antibody. In parallel, luciferase assays were performed and relative luciferase 
activity (the activity in control cell was set as 1.0) was calculated and shown in 
C. D. Construction of HeLa cell line stably expressing Flag-N-RL-NPM1 and 
Flag-C-RL-NPM1, or Flag-N-RL-NPM1 and Flag-C-RL. Expression of proteins 
were detected by anti-NPM1 antibody (D). Flag-C-RL was too small to be 
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detected. -actin was also detected as a control. Luciferase activities of 
different cell numbers from each cell line were examined and relative 
luciferase activity was plotted in E. 
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Figure 4 
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Fig. 4 Change of NPM1 oligomerization state under various cell culture 
conditions 
A. Localization of the p65 subunit of NF-B in HeLa cells treated without or 
with TNF-α. HeLa cells were treated with TNF-α (20 ng/ml) and localization of 
p65 was examined with anti-p65 antibody. DNA was visualized with DAPI 
staining. Scale bar indicates 10 m. B. Effect of TNF-α treatment on the 
oligomerization of NPM1. HeLa cells stably expressing 
N-RL-NPM1/C-RL-NPM1 and N-RL-NPM1/C-RL were treated with TNF-α (20 
ng/ml) for 3–24 hours and luciferase activity of the cells were examined. C, D 
Oligomeric state of NPM1 in asynchronous and mitotic cells. Asynchronous 
and mitotic cell lines were prepared and the expression of NPM1 proteins, 
Cyclin B, and -actin were detected by western blotting. In parallel, luciferase 
activities of the cells were examined and shown in D. E, F. Effect of serum 
starvation on the oligomerization of NPM1. The cell lines were incubated in 
medium contains 0% or 10% FBS for 28 h, and the expression of NPM1 
proteins were detected by western blotting and the luciferase activity was 
detected (F). For the graph in B, D, and F, blank and filled bars indicate the 
luciferase activity for cell line expressing N-RL-NPM1/C-RL and 
N-RL-NPM1/C-RL-NPM1, respectively.  Three independent experiments 
were performed and error bars indicate ±SD. 
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2-6. Discussion 
Various observations have suggested that changes in the oligomeric state 
of NPM1 may influence its biological functions and subcellular localization [23]. 
However, the biochemical function of the oligomerization has been poorly 
understood. In this study, I demonstrated that the oligomerization of NPM1 is 
required for its histone chaperone activity. Thus, it is suggested that the 
histone chaperone function of NPM1 is regulated by monomer-oligomer 
conversion. The nucleolar localization of NPM1 requires its biding to RNA [24], 
and monomeric NPM1 is mainly localized in the nucleoplasm [14], raising the 
possibility that the nucleoplasmic NPM1 may lose its RNA binding activity. 
However, my in vitro result showed that the monomeric and oligomeric NPM1 
showed similar RNA binding activity, indicating that the nucleoplasmic 
localization of NPM1 monomer is not caused by loss of RNA binding activity. 
The nucleoplasmic localization of NPM1 monomer may be caused by 
posttranscriptional modifications, interaction with nucleoplasmic proteins, or 
loss of interaction with nucleolar proteins. 
I also established an assay to systematically study the cellular 
oligomerization of NPM1 using the split synthetic Renilla luciferase protein. By 
using this assay I examined the cellular oligomerization state of NPM1 under 
different cell culture conditions or stimuli. It was reported that IKK promotes 
the oligomerization of NPM1 to induce the localization of NPM1 to centrosome, 
thereby maintains genome integrity, and prevents tumor progression [15]  
Consistent with the previous report, my result showed that TNF-α treatment 
that activated the IKKα enhanced the oligomerization of NPM1. This result 
ensures the usefulness of the assay system. Furthermore, I also examined the 
oligomerization of mitotic NPM1 of which cellular localization is dramatically 
changed [25]. My result showed that mitotic NPM1 shows much higher 
oligomer level compared with interphase NPM1. This may be resulted from the 
phosphorylation of NPM1 during mitosis. Phosphorylations of NPM1 have 
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been reported to affect the functions of NPM1. For example, NPM1 associates 
with unduplicated centrosomes and dissociates from centrosome to allow its 
duplication upon phosphorylation at Thr199 by CDK2/cyclin E during G1 phase 
[15]; phosphorylation of NPM1 during mitosis by cyclin B/Cdc2 inactivates the 
RNA binding of NPM1 resulted the release of NPM1 from chromatin [24, 26]. I 
also showed that serum starvation that can cause the translocation of NPM1 
from the nucleolus to the nucleoplasm [27] decreases the oligomerization of 
NPM1, this may be caused by posttranslational modifications such as 
phosphorylation, or loss of the interaction with R-rich motif containing proteins 
since interaction with R-rich motif containing protein can promote its nucleolar 
localization [23]. Although the biological significance of enhanced oligomer 
formation in mitosis is not clear, the decreased oligomer formation of NPM1 in 
serum starved cells is likely to contribute to the inhibition of ribosome 
biogenesis by excluding NPM1 from the nucleoli. 
These successful detections of changes of NPM1 oligomerization under 
different cell culture conditions suggest that this assay system can be used for 
systematically study the cellular oligomerization of NPM1 under various 
conditions to understand the functions of NPM1. Moreover, it can also be a 
promising method for the screening of NPM1 oligomerization inhibitor for 
cancer therapy. 
 
 
2-7.  
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Chapter 3: Summary, significance and perspective 
NPM1 is a multi-functional protein that might contribute to tumorigenesis in 
different ways. This dissertation describes the mechanisms underlying the 
oncogenic functions of NPM1 in different aspects.  
The first chapter is focused on the function of NPM1 in NF-κB pathway. I found 
that NPM1 contributes to the full activation of NF-κB by enhancing its DNA 
binding activity. NPM1 regulated NF-κB mediated inflammatory genes in both 
cancer cells and normal cells like macrophages suggest the oncogenic role of 
NPM1 in both tumor cells and the tumor microenvironment through the 
regulation of NF-κB. This result suggests that the oncogenic functions of 
NPM1 might result from the sum of comprehensive effect on both cancer cells 
and normal cells, emphasizing the importance of studying the oncogenic 
functions of NPM1 in vivo in future. The correlation between NPM1 expression 
and activation of NF-κB in colon and breast cancer, and its contribution to 
NF-κB activity suggests that the expression level of NPM1 is a suitable 
diagnostic marker to determine the aggressiveness of cancer cells and also a 
suitable target of cancer therapy. In addition to NF-κB, my microarray data 
showed that NPM1 might also regulate other transcription factors that regulate 
the cancer development (data not shown). Thus, it may be important to 
elucidate the interactome between NPM1 and the transcription factors and 
investigate whether there is a consensus mechanism underlying the regulation 
of transcription factors by NPM1. 
The second project is focused on the study of NPM1 oligomerization. Plenty of 
observations have suggested that the implication of NPM1 oligomerization in 
cancer cells than that in normal cells, and inhibition of NPM1 oligomerization 
caused the apoptosis of cancer cells. However, the mechanism is still elusive. 
Here, I reported that the NPM1 oligomerization is required for its histone 
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chaperone activity. Previously, my laboratory reported that the histone 
chaperone activity of NPM1 regulated the ribosomal DNA (rDNA) gene 
transcription through regulation of the histone density on the rDNA gene 
promoters. Since NPM1 oligomerization is required for its histone chaperone 
activity, the oligomerization of NPM1 may be important for the ribosomal 
biogenesis to provide enough “energy” in cancer cells. Moreover, I successfully 
established the system for detection of dynamic NPM1oligomerization in the 
cell, which on the one hand, can be applied for examine the dynamic change of 
NPM1 oligomerization in different conditions for better understanding of the 
oncogenic functions of NPM1, on the other hand, it can also be used for 
screening of NPM1 oligomer inhibitors for cancer therapy.  
This dissertation suggests the complex oncogenic functions of NPM1, which 
could be the regulation of transcription factor or ribosomal biogenesis, or other 
undiscovered mechanisms. Due to the multiple roles NPM1 plays in cancer, it 
may be the suitable target for cancer therapy.  
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